GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » Short Interest

DaVita (BSP:DVAI34) Short Interest


View and export this data going back to 2019. Start your Free Trial

What is DaVita Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of DaVita's Short Interest

For the Medical Care Facilities subindustry, DaVita's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DaVita's Short Interest Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Short Interest distribution charts can be found below:

* The bar in red indicates where DaVita's Short Interest falls into.


DaVita (BSP:DVAI34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » Short Interest
Comparable Companies
UHS THC CHE EHC ACHC ENSG OPCH PACS SEM SGRY HCA SAU:4013 SZSE:300015 XTER:FRE BKK:BDMS ADX:PUREHEALTH XTER:FME XKLS:5225 HKSE:06618 BSP:RDOR3
Traded in Other Exchanges
DVA:USA TRL:Germany
Address
2000 16th Street, Denver, CO, USA, 80202
Website
https://www.davita.com
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

DaVita (BSP:DVAI34) Headlines

No Headlines